Aller au contenu

Lilly's Retatrutide Beat Ozempic 2 mg on Blood Sugar and Weight Loss in Head-to-Head Diabetes Trial

29 octobre 2026 · 16 min

Notes de l’épisode

Eli Lilly says its investigational once-weekly drug retatrutide beat Novo Nordisk's Ozempic 2 mg in TRANSCEND-T2D-2, the first Phase 3 trial comparing retatrutide head-to-head with another incretin medicine. We walk through the topline results Lilly announced on October 28, 2026 for 1,298 adults with type 2 diabetes not controlled on metformin, with or without an SGLT2 inhibitor: at 80 weeks, A1C fell by an average of 2.2 percentage points on both retatrutide doses (9 mg and 12 mg) versus 1.8 on Ozempic 2 mg, and body weight fell 19.5% and 20.9% versus 9.4%. We explain why only the 12 mg A1C superiority result was statistically controlled while the 9 mg A1C difference was "nominal," that the figures use the efficacy estimand, and that full results have not yet been peer reviewed. We also note what Lilly said about certain cardiovascular risk factors (non-HDL cholesterol, triglycerides and systolic blood pressure) and one Leerink analyst's 2032 sales estimate, and we cover the trade-off: more gastrointestinal side effects and higher discontinuation rates due to adverse events on retatrutide (4.8% and 7.9% versus 2.7% on Ozempic). Retatrutide is not approved anywhere, and Lilly says anyone selling it to consumers is breaking the law. Sources: - Eli Lilly news release, "Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial" (Oct 28, 2026): https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more - ClinicalTrials.gov, TRANSCEND-T2D-2 (NCT06260722): https://clinicaltrials.gov/study/NCT06260722 - BioPharma Dive, "Lilly's 'triple-G' drug tops Novo's Ozempic in diabetes trial" (Oct 28, 2026): https://www.biopharmadive.com/news/retatrutide-ozempic-diabetes-trial-results-lilly-novo/873016/ - Reuters via Yahoo News, "Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial" (Oct 28, 2026): https://www.yahoo.com/news/science/articles/lillys-next-gen-drug-outshines-104705473.html Cover: original illustration made for this episode (three linked spheres beside one); no photo used. This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. Visit glp1newspaper.com to see today's stories and sign up for free email alerts.

Tous les épisodes de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Paramètres

Affichage

Langue

Détermine les stations affichées en premier sur la page d’accueil.

Historique

Les stations et épisodes écoutés récemment et tes dernières recherches sont seulement enregistrés dans ce navigateur.

Notifications

Un court message quand un podcast que tu suis publie un nouvel épisode. Désactive un podcast précis avec la cloche sur sa page.

Compte

Enregistrez vos favoris – dans l’app et sur le site.

Raccourcis clavier

/
Ouvrir la recherche
Espace
Lecture ou pause
← →
Dans le lecteur : 15 s en arrière, 30 s en avant (épisodes) · dans une rangée : tuile suivante
↑ ↓
Dans une rangée : cible dans la tuile
Début / Fin
Dans une rangée : première ou dernière tuile
Esc
Fermer la fenêtre ou le menu
?
Cet aperçu
En cours de lecture

Voir la station

À suivre

    Ajoutez des épisodes avec « À suivre » – ils seront lus après l'épisode en cours.